TICKERNOMICS Sign up
Last Update: 2023-12-23 06:00:10
MIMEDX GROUP INC. ( MDXG ) https://www.mimedx.com
8.98USD
Sector:
Healthcare
Industry:
Biotechnology
Country:
United States
1y
3y
5y
10y
Historical Returns*:
SPY
23.45%
MDXG
224.19%
SPY
30.72%
-5.47%
MDXG
SPY
112.82%
MDXG
498.67%
SPY
201.04%
MDXG
7.03%
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
1071.56
1088.33
0.49
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
247.13
3.47
805.69
0.06
0.00
77.22
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
13.24
81.90
4.56
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
11.8502
10.94
15.39
1.93
Other Earnings and Cash Flow Stats:
MIMEDX GROUP INC. ( MDXG ) Net Income TTM ($MM) is -5.29
MIMEDX GROUP INC. ( MDXG ) Operating Income TTM ($MM) is 1.40
MIMEDX GROUP INC. ( MDXG ) Owners' Earnings Annual ($MM) is -20.68
MIMEDX GROUP INC. ( MDXG ) Current Price to Owners' Earnings ratio is -15.18
MIMEDX GROUP INC. ( MDXG ) EBITDA TTM ($MM) is 3.50
MIMEDX GROUP INC. ( MDXG ) EBITDA Margin is 4.56%
Capital Allocation:
MIMEDX GROUP INC. ( MDXG ) has paid 0.00 dividends per share and bought back -5.879458 million shares in the past 12 months
MIMEDX GROUP INC. ( MDXG ) has increased its debt by 0.982 million USD in the last 12 months
Capital Structure:
MIMEDX GROUP INC. ( MDXG ) Interest-bearing Debt ($MM) as of last quarter is 97
MIMEDX GROUP INC. ( MDXG ) Annual Working Capital Investments ($MM) are -61
MIMEDX GROUP INC. ( MDXG ) Book Value ($MM) as of last quarter is 1
MIMEDX GROUP INC. ( MDXG ) Debt/Capital as of last quarter is 7363%
Other Balance Sheet Stats:
MIMEDX GROUP INC. ( MDXG ) has 81 million in cash on hand as of last quarter
MIMEDX GROUP INC. ( MDXG ) has 43 million of liabilities due within 12 months, and long term debt 48 as of last quarter
MIMEDX GROUP INC. ( MDXG ) has 119 common shares outstanding as of last quarter
MIMEDX GROUP INC. ( MDXG ) has 0 million USD of preferred stock value
Academic Scores:
MIMEDX GROUP INC. ( MDXG ) Altman Z-Score is 4.58 as of last quarter
MIMEDX GROUP INC. ( MDXG ) Piotroski Score is 7.00 as of last quarter
Corporate Governance:
MIMEDX GROUP INC. ( MDXG ) largest shareholder is Northern Trust Corp owning 1070716 shares at 9.62 ($MM) value
Rice Doug(an insider) Bought 5000 shares of MIMEDX GROUP INC. ( MDXG ) for the amount of $35800.00 on 2023-11-21
4.90% of MIMEDX GROUP INC. ( MDXG ) is held by insiders, and 66.97% is held by institutions
MIMEDX GROUP INC. ( MDXG ) went public on 2007-08-22
Other MIMEDX GROUP INC. ( MDXG ) financial metrics:
FCF:0.67
Unlevered Free Cash Flow:-98.59
EPS:0.29
Operating Margin:13.24
Gross Profit Margin:81.90
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:2566.62
Beta:1.93
Buffet's Owners Earnings:-20.68
Price to Owner's Earnings:-15.18
About MIMEDX GROUP INC. ( MDXG ) :
MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins. The company's patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. Its products include EpiFix, a semi-permeable protective barrier membrane product used for the treatment of chronic wounds, including diabetic foot ulcers, venous leg ulcers, and pressure ulcers; AmnioFix, a semi-permeable protective barrier allograft, which comprises dehydrated human amnion/chorion membrane for use in surgical recovery applications; EpiCord and AmnioCord are dehydrated human umbilical cord allografts that are used to provide a protective environment for the healing process, as well as used in the advanced wound care and surgical recovery applications; and AMNIOBURN a semi-permeable protective barrier allograft used in the treatment of partial-thickness and full-thickness burns, as well as lead product includes mdHACM, a micronized form of AMNIOFIX, supplied in powder form. The company's products have applications primarily in the areas of wound care, burn, surgical, and non-operative sports medicine sectors of healthcare. It also sells allografts for dental applications on an original equipment manufacturer basis. The company sells its products through direct sales force and independent sales agents, as well as through independent distributors primarily in the United States. MiMedx Group, Inc. was incorporated in 2011 and is headquartered in Marietta, Georgia.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.